A characteristic selective serotonin reuptake inhibitor (SSRI) discontinuation syndrome appears to exist. It is usually mild, commences within 1 week of stopping treatment, resolves spontaneously within 3 weeks, and consists of diverse physical and psychological symptoms, the commonest being dizziness, nausea, lethargy and headache. SSRI reinstatement leads to resolution within 48 h. A transient stage of serotonin dysregulation appears central to causation with pharmacokinetic and pharmacodynamic differences accounting for the variation in incidence between the SSRIs. Discontinuation reactions are clinically relevant due to the associated morbidity, the potential for misdiagnosis and inappropriate treatment and because they may impair future antidepressant compliance. To minimize incidence, SSRIs, like other antidepressants, should be withdrawn gradually Provisional diagnostic criteria for the SSRI discontinuation syndrome are proposed. Prospective studies are required to investigate the syndrome, particularly its effects on patient care.
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington DC
2.
Australian Adverse Drug Reactions Advisory Committee (1996) SSRIs and withdrawal syndrome. Aust Adv Drug React Bull15: 3
3.
Barr L.C., Goodman W.K., Price LH (1994) Physical symptoms associated with paroxetine discontinuation . Am J Psychiat151: 289
4.
Berlin C.S. (1996) Fluoxetine withdrawal symptoms. J Clin Psychiat57: 93-94
5.
Bertilsson L., Dahl M.L., Sjoqvist F., Aberg-Wistedt A., Humble M., Johansson I., Lundqvist E., Ingelman-Sundberg M. (1993) Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet341: 63
6.
Bhaumik S., Wildgust H.J. (1996) Letter to the editor. Human Psychopharmac11: 337-338
7.
Bialos D., Giller E., Jatlow P., Docherty J., Harkness K. (1982) Recurrence of depression after discontinuation of amitriptyline. Am J Psychiat139: 325-329
8.
Black D.W., Wesner R., Gabel J. (1993) The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiat54: 146-149
9.
Black K., Shea C., Dursun S., Kutcher S. (1997) Selective serotonin reuptake inhibitor (SSRI) withdrawal syndrome: proposed diagnostic criteria (abstract). J Psychopharmac11 (Suppl.3): A31, poster 121
10.
Bloch M., Stager S.V., Braun A.R., Rubinow D.R. (1995) Severe psychiatric symptoms associated with paroxetine withdrawal. Lancet346: 57
11.
Blomgren S.L., Krebs W., Wilson M., Ascroft R., Fave M., Rosenbaum J. (1997) SSRI dose interruption study: interim data (abstract) . American Psychiatric Association, 150th Annual Meeting, San Diego, CA, May 17-22 1997 . New Research Abstracts: NR 188. American Psychiatric Association, Washington DC
12.
British National Formulary (1998) The Pharmaceutical Press, London
13.
Brosen K., Gram L.F. (1989) Clinical significance of the sparteine/ debrisoquine oxidation polymorphism. Eur J Clin Pharmac36: 537-547
14.
Coccaro E.F. (1989) Central serotonin and impulsive aggression. Br J Psychiat155 (Suppl. 8): 52-62
15.
Committee on Safety of Medicines (1993) Dystonias and withdrawal symptoms with paroxetine (seroxat). Curr Prob Pharmacovigilance19:1
Dahl M.L., Olhager E., Ahlner J. (1997) Paroxetine withdrawal syndrome in a neonate. Br J Psychiat171: 391-392
18.
Debattista C., Schatzberg A.F. (1995) Physical symptoms associated with paroxetine withdrawal . Am J Psychiat152: 1235-1236
19.
Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landi H., Nheninger G.R. (1990) Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Archs Gen Psychiat47: 411-418
20.
Diamond B.I., Borison R.L., Katz R. et al. (1989) Rebound reactions due to clomipramine. Psychopharmac Bull255: 209-212
21.
Dilsaver S.C., Greden J.F., Snider R.M. (1987) Antidepressant withdrawal syndromes: phenomenology and physiology. Int Clin Psychopharmac2:1-19
22.
Dominguez RA, Goodnick PJ (1996) Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy15: 778-780
23.
Einbinder E. (1995) Fluoxetine withdrawal? Am J Psychiat152:1253
24.
Ellison J.M. (1993) SSRI withdrawal buzz. Am J Psychiat55:544-545
25.
Farah A., LauerT. ( 1996) Possible venlafaxine withdrawal syndrome. Am J Psychiat153: 576
26.
Fava G.A., Grandi S. (1995) Withdrawal syndromes after paroxetine and sertraline discontinuation. J Clin Psychopharmac15: 374-375
27.
Feiger A.D., Bielski R.D., Bremmer J., Heiser J., Trivedi M., Wilcox C.S. (1996) Efficacy of nefazodone in continuation treatment of depression. Psychopharmac Bull32: 444
28.
Frost L., Lal S. ( 1995) Shock-like sensations after discontinuation of selective serotonin reuptake inhibitor. Am J Psychiat152: 810
29.
Gardos G., Cole JO, Tarsy D. (1978) Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiat135:1321-1324
30.
Geller B., CooperT B., Carr L.G. (1987) Prospective study of scheduled withdrawal from nortriptyline in children and adolescents. J Clin Psychopharmac7: 252-254
31.
Jacobs B.L., Fornal C.A. (1953) 5-HT and motor control: a hypothesis. Trends Neurosci16: 346-352
32.
Johnson A.M. (1993) The comparative pharmacological properties of selective serotonin re-uptake inhibitors in animals. In Feighner J P, Boyer W F (eds), Selective serotonin re-uptake inhibitors. John Wiley, Chichester
33.
Kent Lsw, Laidlaw J D D (1995) Suspected congenital sertraline dependence. Br J Psychiat167: 412-413
34.
Keuthen NJ, Cyr P., Ricciardi JA, Minichiello W.E., Battolph M.L., Jenike M.A. (1994) Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmac14: 206-207
35.
Keyser D.L., Rodnitzky R.L. (1991) Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Archs Int Med151: 794-796
36.
Koopowitz L.F., Berk M. ( 1995) Paroxetine induced withdrawal effects. Hum Psychopharmac10: 147-148
37.
Kramer JC, Klein DF, Fink M. ( 1961) Withdrawal symptoms following discontinuation of imipramine therapy. Am J Psychiat118: 549-550
38.
Law W., Petti TA, Kazadin A. (1981) Withdrawal symptoms after graduated cessation of imipramine in children. Am J Psychiat118: 647-650
39.
Lejoyeux M., Ades J., Mourad I., Solomon J., Dilsaver S. (1996) Antidepressant withdrawal syndrome. CNS Drugs5: 278-292
40.
Louie A.K., Lannon R.A., Kirsch M.A., Lewis T.B. (1996) Venlafaxine withdrawal reactions. Am J Psychiat153:1652
41.
Mallya G., White K., Gunderson C. (1993) Is there a serotonergic withdrawal syndrome. Biol Psychiat33: 849-855
42.
Mander A.J., Loudon J.B. (1988) Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet339: 15-17
43.
Mann A.M., MacPherson AS (1959) Clinical experience with imipramine (G22355) in the treatment of depression. Can Psychiat Ass J4: 38-47
44.
Meyer UA, Zanger U.M., Grant D., Blum M. ( 1990) Genetic polymorphisms of drug metabolism. Adv Drug Res19: 197-241
45.
Michelson D., Onawala R., Beasley M. (1997) Abrupt discontinuation of fluoxetine: a randomised placebo-controlled study (abstract). American Psychiatric Association, 150th Annual Meeting, San Diego, CA, May 17-22 1997. New Research Abstracts: NR200. American Psychiatric Association, Washington DC
46.
Oehrberg S., Christiansen P.E., Behnke K., Borup A.L., Severin B., Soegaard J., Calberg H., Juitge R., Ohrstrom J.K., Manniche P.M. (1995) Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br J Psychiat167: 374-379
47.
Otani K., Tanaka O., Kaneko S. et al. (1994) Mechanisms of the development of trazodone withdrawal symptoms. Int Clin Psychopharmac9:131-133
48.
Pacheco L., Malo P., Aragues E., Etxebeste M. (1996) More cases of paroxetine withdrawal syndrome. Br J Psychiat169: 384
49.
Page R.C. (1997) How to wean a patient off corticosteroids. Prescribers' J37: 11-16
50.
Philips S.D. (1995) A possible paroxetine withdrawal syndrome. Am J Psychiat152: 645-646
51.
Preskorn S.H. (1996) Clinical pharmacology of selective serotonin reuptake inhibitors, 1st edn. Professional Communications, Inc., Caddo, p. 118
52.
Price J.S., Waller P.C., Wood S.M., Mackay A V P (1996) A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors, including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmac42: 757-763
53.
Priest R.G., Vize C., Roberts A., Tylee A. (1996) Lay people's attitudes to treatment of depression: result of opinion poll for Defeat Depression Campaign just before its launch . BMJ313: 858-859
Rosenstock H.A. (1996) Sertraline withdrawal in two brothers: a case report . Int Clin Psychopharmac11: 58-59
57.
Rothchild A.J. (1995) Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiat152: 1514-1516
58.
Routledge PA, Bialas M.C. (1997) Adverse reactions to drug withdrawal. Adv Drug React Bull187: 711-714
59.
Simpson C.J. (1984) Doctors' and nurses' use of the word 'confused' . Br J Psychiat145: 441-443
60.
Spencer M.J. (1993) Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics92: 721-722
61.
Stoukides JA, Stoukides C.A. (1991) Extrapyramidal symptoms upon discontinuation of fluoxetine. Am J Psychiat148:1263
62.
Szabadi E. (1992) Fluvoxamine withdrawal syndrome. Br J Psychiat160: 283-284
63.
Thomas D.R., Nelson D.R., Johnson A.M. (1987) Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology93:193-200
64.
Tyrer P. (1984) Clinical effects of abrupt withdrawal from tricyclic antidepressants and monoamine oxidase inhibitors after long term treatment . J Affect Disord6:1-7
65.
Young AH, Currie A. (1997) Physicians' knowledge of antidepressant withdrawal effects: a survey. J Clin Psychiat58 (Suppl. 7): 28-30
66.
Young A.H., Currie A., Ashton C.H. (1997) Antidepressant withdrawal syndrome. Br J Psychiat170: 288
